Clayton Smith, MD
OncoVerity, Inc. · Duke Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Clayton Smith, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04150887 · Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaOncoVerity, Inc. · active not recruiting · Leukemia, Myeloid, Acute · study director
- Ph2NCT04023526 · A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive ChemotherapyOncoVerity, Inc. · active not recruiting · Leukemia, Myeloid, Acute · study director
- Ph1NCT00003435 · Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic CancerDuke University · withdrawn · Leukemia, Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.